Particle-to-PFU ratio of ebola virus influences disease course and survival in cynomolgus macaques

Journal of Virology

Volumn 89, Issue 13, 2015, Pages 6773-6781

  Alfson, Kendra J ^a,b   Avena, Laura E ^a   Beadles, Michael W ^a,e   Staples, Hilary ^a   Nunneley, Jerritt W ^a,f   Ticer, Anysha ^a   Dick, Edward J ^c   Owston, Michael A ^c   Reed, Christopher ^d,g   Patterson, Jean L ^a   Carrion, Ricardo ^a   Griffiths, Anthony ^a,b  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^e Bexar County Medical Examiner's Office   (United States)

^f ENV Services Inc   (United States)

^g VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; EBOLAVIRUS; FILOVIRUS; FILOVIRUS INFECTION; HEMORRHAGIC FEVER; IMMUNE RESPONSE; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MICROBIOLOGICAL PARAMETERS; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS SURVIVAL; VIRUS VIRULENCE; ANIMAL; EBOLA HEMORRHAGIC FEVER; GROWTH, DEVELOPMENT AND AGING; HAPLORHINI; MORTALITY; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; SURVIVAL ANALYSIS; VIRAL PLAQUE ASSAY; VIROLOGY; VIRULENCE; VIRUS CULTURE; VIRUS LOAD;

ANIMALIA; EBOLA VIRUS; MACACA; MACACA FASCICULARIS; MAMMALIA; MARBURGVIRUS; PRIMATES; RNA VIRUSES;

ANIMALS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; HAPLORHINI; HEMORRHAGIC FEVER, EBOLA; MACACA FASCICULARIS; SERIAL PASSAGE; SURVIVAL ANALYSIS; VIRAL LOAD; VIRAL PLAQUE ASSAY; VIRULENCE;

EID: 84930886364     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00649-15     Document Type: Article

References (36)

1. WHO Ebola Response Team. 2014. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med 371:1481-1495. http://dx.doi.org/10.1056/NEJMoa1411100.
2. Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, Rollin PE, Zaki SR, Peters CJ. 1996. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 2:321-325. http://dx.doi.org/10.3201/eid0204.960407.
3. Marsh GA, Haining J, Robinson R, Foord A, Yamada M, Barr JA, Payne J, White J, Yu M, Bingham J, Rollin PE, Nichol ST, Wang L-F, Middleton D. 2011. Ebola Reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis 204:S804-S809. http://dx .doi.org/10.1093/infdis/jir300.
4. Miranda MEG, Miranda NLJ. 2011. Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis 204(Suppl 3):S757-S760. http://dx.doi.org/10.1093/infdis/jir296.
5. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, Reeder SA, Quan PL, Lipkin WI, Downing R, Tappero JW, Okware S, Lutwama J, Bakamutumaho B, Kayiwa J, Comer JA, Rollin PE, Ksiazek TG, Nichol ST. 2008. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 4:e1000212. http://dx.doi .org/10.1371/journal.ppat.1000212.
6. Martina BEE, Osterhaus ADME. 2009. "Filoviruses": a real pandemic threat? EMBO Mol Med 1:10-18. http://dx.doi.org/10.1002/emmm .200900005.
7. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S. 2014. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371:1418-1425. http://dx.doi.org/10.1056/NEJMoa1404505.
8. Code of Federal Regulations. 2014. Title 21. Food and drugs. Chapter I. Food and Drug Administration. Subchapter D. Drugs for human use. Part 314. Applications for FDA approval to market a new drug. Subpart I. Approval of new drugs when human efficacy studies are not ethical or feasible. 21 CFR 314.600.
9. Code of Federal Regulations. 2014. Title 21. Food and drugs. Chapter I. Food and Drug Administration. Subchapter F. Biologics. Part 601. Licensing. Subpart H. Approval of biological products when human efficacy studies are not ethical or feasible. 21 CFR 601.90.
10. Food and Drug Administration. 2002. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist 67:37988-37998.
11. Gronvall GK, Trent D, Borio L, Brey R, Nagao L. 2007. The FDA animal efficacy rule and biodefense. Nat Biotechnol 25:1084-1087. http://dx.doi .org/10.1038/nbt1007-1084.
12. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. 2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7:393-400. http://dx.doi.org/10.1038/nrmicro2129.
13. Institute of Medicine National Research Council. 2014. Research priorities to inform public health and medical practice for Ebola virus disease:workshop in brief. The National Academies Press, Washington, DC.
14. Schwerdt CE, Fogh J. 1957. The ratio of physical particles per infectious unit observed for poliomyelitis viruses. Virology 4:41-52. http://dx.doi .org/10.1016/0042-6822(57)90042-9.
15. Carpenter JE, Henderson EP, Grose C. 2009. Enumeration of an extremely high particle-to-PFU ratio for varicella-zoster virus. J Virol 83:6917-6921. http://dx.doi.org/10.1128/JVI.00081-09.
16. Frey TK. 1994. Molecular biology of rubella virus. Adv Virus Res 44:69-160. http://dx.doi.org/10.1016/S0065-3527(08)60328-0.
17. Coffey LL, Vignuzzi M. 2011. Host alternation of Chikungunya virus increases fitness while restricting population diversity and adaptability to novel selective pressures. J Virol 85:1025-1035. http://dx.doi.org/10.1128/JVI.01918-10.
18. Luria SE, Anderson TF. 1942. The identification and characterization of bacteriophages with the electron microscope. Proc Natl Acad Sci U S A 28:127-130.1. http://dx.doi.org/10.1073/pnas.28.4.127.
19. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. 1999. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 179(Suppl 1):S248-S258. http://dx.doi.org/10.1086/514292.
20. Weidmann M, Sall A, Manuguerra J-C, Koivogui L, Adjami A, Traore F, Hedlund K-O, Lindegren G, Mirazimi A. 2011. Quantitative analysis of particles, genomes and infectious particles in supernatants of haemorrhagic fever virus cell cultures. Virology J 8:81. http://dx.doi.org/10.1186/1743-422X-8-81.
21. Sobrino F, Dávila M, Ortín J, Domingo E. 1983. Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology 128:310-318. http://dx.doi.org/10.1016/0042-6822(83)90258-1.
22. Domingo E, Escarmís C, Sevilla N, Moya A, Elena SF, Quer J, Novella IS, Holland JJ. 1996. Basic concepts in RNA virus evolution. FASEB J 10:859-864.
23. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S. 1982. Rapid evolution ofRNAgenomes. Science 215:1577-1585. http://dx .doi.org/10.1126/science.7041255.
24. Thompson K, Yin J. 2010. Population dynamics of an RNA virus and its defective interfering particles in passage cultures. Virology J 7:257. http://dx.doi.org/10.1186/1743-422X-7-257.
25. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
26. Kugelman JR, Lee MS, Rossi CA, McCarthy SE, Radoshitzky SR, Dye JM, Hensley LE, Honko A, Kuhn JH, Jahrling PB, Warren TK, Whitehouse CA, Bavari S, Palacios G. 2012. Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One 7:e50316. http://dx.doi.org/10.1371/journal.pone.0050316.
27. Shurtleff A, Biggins J, Keeney A, Zumbrun E, Bloomfield H, Kuehne A, Audet J, Alfson K, Griffiths A, Olinger G, Bavari S. 2012. Standardization of the filovirus plaque assay for use in preclinical studies. Viruses 4:3511-3530. http://dx.doi.org/10.3390/v4123511.
28. Trombley AR, Wachter L, Garrison J, Buckley-Beason VA, Jahrling J, Hensley LE, Schoepp RJ, Norwood DA, Goba A, Fair JN, Kulesh DA. 2010. Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg 82:954-960. http://dx.doi.org/10.4269/ajtmh.2010.09-0636.
29. Chamanza R, Marxfeld HA, Blanco AI, Naylor SW, Bradley AE. 2010. Incidences and range of spontaneous findings in control cynomolgus monkeys (Macaca fascicularis) used in toxicity studies. Toxicol Pathol 38:642-657. http://dx.doi.org/10.1177/0192623310368981.
30. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:2347-2370. http://dx.doi.org/10.1016/S0002-9440(10)63591-2.
31. Baskerville A, Bowen ET, Platt GS, McArdell LB, Simpson DI. 1978. The pathology of experimental Ebola virus infection in monkeys. J Pathol 125:131-138. http://dx.doi.org/10.1002/path.1711250303.
32. Nakayama E, Saijo M. 2013. Animal models for Ebola and Marburg virus infections. Front Microbiol 4:267. http://dx.doi.org/10.3389/fmicb.2013.00267.
33. Calain P, Monroe MC, Nichol ST. 1999. Ebola virus defective interfering particles and persistent infection. Virology 262:114-128. http://dx.doi .org/10.1006/viro.1999.9915.
34. Booth TF, Rabb MJ, Beniac DR. 2013. How do filovirus filaments bend without breaking? Trends Microbiol 21:583-593. http://dx.doi.org/10.1016/j.tim.2013.08.001.
35. Stroher U, West E, Bugany H, Klenk HD, Schnittler HJ, Feldmann H. 2001. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 75:11025-11033. http://dx.doi.org/10.1128/JVI.75.22.11025-11033.2001.
36. Beniac DR, Melito PL, Devarennes SL, Hiebert SL, Rabb MJ, Lamboo LL, Jones SM, Booth TF. 2012. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PLoS One 7:e29608. http://dx .doi.org/10.1371/journal.pone.0029608.